Literature DB >> 30948491

Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial.

Rohtesh S Mehta1, Roland Bassett2, Amanda Olson1, Julianne Chen1, Sairah Ahmed1, Amin M Alousi1, Paolo Anderlini1, Gheath Al-Atrash1, Qaiser Bashir1, Stefan O Ciurea1, Chitra M Hosing1, Jin S Im1, Partow Kebriaei1, Issa Khouri1, David Marin1, Jeffrey J Molldrem1, Yago Nieto1, Betul Oran1, Katayoun Rezvani1, Muzaffar H Qazilbash1, Samer A Srour1, Elizabeth J Shpall1, Borje S Andersson1, Richard E Champlin1, Uday R Popat3.   

Abstract

Entities:  

Year:  2019        PMID： 30948491      PMCID： PMC6959196          DOI： 10.3324/haematol.2018.214429

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.

Authors:  Roland B Walter; Ted A Gooley; Brent L Wood; Filippo Milano; Min Fang; Mohamed L Sorror; Elihu H Estey; Alexander I Salter; Emily Lansverk; Jason W Chien; Ajay K Gopal; Frederick R Appelbaum; John M Pagel
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

2.  Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.

Authors:  Christopher G Kanakry; Paul V O'Donnell; Terry Furlong; Marcos J de Lima; Wei Wei; Marta Medeot; Marco Mielcarek; Richard E Champlin; Richard J Jones; Peter F Thall; Borje S Andersson; Leo Luznik
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

3.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

4.  Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.

Authors:  Brian L McClune; Daniel J Weisdorf; Tanya L Pedersen; Gisela Tunes da Silva; Martin S Tallman; Jorge Sierra; John Dipersio; Armand Keating; Robert P Gale; Biju George; Vikas Gupta; Theresa Hahn; Luis Isola; Madan Jagasia; Hillard Lazarus; David Marks; Richard Maziarz; Edmund K Waller; Chris Bredeson; Sergio Giralt
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

5.  Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.

Authors:  Daniel J Weisdorf; Heather R Millard; Mary M Horowitz; Parvinder S Hyare; Richard Champlin; Vincent Ho; Marco Mielcarek; Andrew Rezvani; Keith Stockerl-Goldstein; Hanna J Khoury; Marcos De Lima; Wael Saber; Brenda Sandmaier; Mei Jie Zhang; Mary Eapen
Journal:  Cancer       Date:  2017-01-24       Impact factor: 6.860

6.  Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.

Authors:  Z Y Lim; W Ingram; R Brand; A Ho; M Kenyon; S Devereux; J Marsh; G J Mufti; A Pagliuca
Journal:  Bone Marrow Transplant       Date:  2009-09-21       Impact factor: 5.483

7.  Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

Authors:  Mohamed L Sorror; Brenda M Sandmaier; Barry E Storer; Michael B Maris; Frédéric Baron; David G Maloney; Bart L Scott; H Joachim Deeg; Frederick R Appelbaum; Rainer Storb
Journal:  J Clin Oncol       Date:  2007-08-27       Impact factor: 44.544

8.  Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years).

Authors:  M Pohlen; C Groth; T Sauer; D Görlich; R Mesters; C Schliemann; G Lenz; C Müller-Tidow; T Büchner; W E Berdel; M Stelljes
Journal:  Bone Marrow Transplant       Date:  2016-06-13       Impact factor: 5.483

9.  Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.

Authors:  Roland B Walter; Sarah A Buckley; John M Pagel; Brent L Wood; Barry E Storer; Brenda M Sandmaier; Min Fang; Boglarka Gyurkocza; Colleen Delaney; Jerald P Radich; Elihu H Estey; Frederick R Appelbaum
Journal:  Blood       Date:  2013-07-11       Impact factor: 22.113

10.  Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.

Authors:  Uday R Popat; Rohtesh S Mehta; Roland Bassett; Julianne Chen; Benigno C Valdez; Jitesh Kawedia; Sairah Ahmed; Amin M Alousi; Paolo Anderlini; Geath Al-Atrash; Qaiser Bashir; Stefan O Ciurea; Chitra M Hosing; Jin S Im; Roy Jones; Partow Kebriaei; Issa Khouri; David Marin; Yago Nieto; Amanda Olson; Betul Oran; Simrit Parmar; Katayoun Rezvani; Muzaffar H Qazilbash; Nina Shah; Samer A Srour; Elizabeth J Shpall; Richard E Champlin; Borje S Andersson
Journal:  Lancet Haematol       Date:  2018-11       Impact factor: 18.959
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.